Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACEPHEN vs AZMIRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Azmiro is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in target tissues, thereby modulating estrogenic effects.
Mild to moderate pain,Fever
Treatment of Ductal Carcinoma In Situ (DCIS) following breast surgery and radiation,Breast cancer risk reduction in premenopausal women at high risk,Off-label: Anovulatory infertility, Osteoporosis prevention in postmenopausal women
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Administer 600 mg intravenously over 60 minutes every 8 hours for 7-14 days.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Terminal elimination half-life: 4.5 hours (range 3–6 h); supports twice-daily dosing.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily metabolized via hepatic glucuronidation by UGT1A4 and UGT1A8; minor metabolism by CYP3A4; excreted mainly in feces.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
98% bound to albumin and alpha-1-acid glycoprotein.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
0.8 L/kg; indicates moderate tissue distribution.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Oral: 60% (first-pass metabolism reduces to ~60% absolute).
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Cr Cl ≥50 m L/min: no adjustment; Cr Cl 30-49 m L/min: 400 mg every 8 hours; Cr Cl 15-29 m L/min: 300 mg every 12 hours; Cr Cl <15 m L/min or hemodialysis: 300 mg every 24 hours.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Child-Pugh A: no adjustment; Child-Pugh B: 400 mg every 8 hours; Child-Pugh C: 300 mg every 12 hours.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
For children ≥2 years: 10 mg/kg/dose IV every 8 hours, maximum 600 mg/dose.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
No specific dose adjustment based solely on age; dose based on renal function as per renal adjustment guidelines.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Increased risk of thromboembolic events including deep vein thrombosis and pulmonary embolism; increased risk of endometrial cancer, uterine sarcoma, and stroke.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Risk of thromboembolic events; endometrial hyperplasia and malignancy; hepatic steatosis and elevated liver enzymes; cataracts; hypertriglyceridemia; use in pregnancy category N (should not be used during pregnancy).
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
History of venous thromboembolism; pregnancy; women with a history of stroke or transient ischemic attack; hypersensitivity to azmiro or its components.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
No significant food interactions. Avoid grapefruit juice as it may increase systemic budesonide exposure. Maintain adequate calcium and vitamin D intake due to potential bone density loss with long-term use.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
No human data; animal studies not conducted. Avoid in pregnancy unless benefit outweighs unknown risks. FDA Pregnancy Category N (not classified).
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No data on excretion in human milk; unknown M/P ratio. Risk to infant cannot be excluded; consider developmental benefits of breastfeeding versus theoretical risk.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
No specific dose adjustments studied; pharmacokinetics in pregnancy unknown. Use lowest effective dose and monitor therapeutic response.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
AZMIRO (budesonide/albuterol) is a fixed-dose combination inhaler for asthma. Due to its LABA component, it should not be used for acute bronchospasm. Titrate to the lowest effective dose. Rinse mouth after inhalation to reduce oral candidiasis and dysphonia. Monitor for increased heart rate and blood pressure, especially with excessive use.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
Use AZMIRO exactly as prescribed, not for sudden breathing problems.,Rinse your mouth with water after each use to prevent thrush.,Do not stop taking this medication without talking to your doctor.,Tell your doctor if symptoms worsen or you need more rescue inhaler.,Avoid foods high in potassium if you are also taking diuretics.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACEPHEN vs AZMIRO, answered by our medical review team.
ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. AZMIRO is a Anticonvulsant that works by Azmiro is a selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in target tissues, thereby modulating estrogenic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACEPHEN and AZMIRO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of AZMIRO is: Administer 600 mg intravenously over 60 minutes every 8 hours for 7-14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACEPHEN and AZMIRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. AZMIRO is classified as Category C. No human data; animal studies not conducted. Avoid in pregnancy unless benefit outweighs unknown risks. FDA Pregnancy Category N (not classified).. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.